Wednesday, August 09, 2023
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Second Quarter Reported With Trial Progress. MAIA reported a 2Q23 loss of $(4.5) million or $(0.35) per share, consistent with our expectations. The company gave updates to its Phase 2 THIO-101 clinical trial testing THIO in non-small cell lung cancer (NSCLC), including continued enrollment and survival of patients treated to date. Cash as of June 30, 2023 was $9.1 million.
THIO-101 Trial Update. The THIO-101 trial tests THIO in combination with Libtayo, (cemiplimab, a PD-1 checkpoint inhibitor from Regeneron) giving two mechanisms of action against the cancer cell. Patients in the trial have progressive or relapsing non-small cell lung cancer after being treated with a checkpoint inhibitor. As of July 2023, 35 patients have been enrolled, an increase over the 29 patients last reported in June 2023. We expect top-line Overall Response Rate data in late fall (3Q/4Q) 2023.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.